Could a new drug ease nerve pain in a rare disease?
NCT ID NCT07699770
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial investigates whether the drug crisugabalin can reduce neuropathic pain in people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition affecting the nerves. Participants will receive either crisugabalin or a placebo, and their pain levels will be tracked using a standard rating scale. The study aims to see if crisugabalin offers meaningful pain relief for this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- crisugabalin
- What this could lead to
- If it works, this could provide a new option for managing chronic pain in NMOSD, improving quality of life.
- What could go wrong
- This is an early exploratory trial with a small number of participants, so results may not be conclusive or apply to everyone. Side effects of crisugabalin are not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS (NMOSD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tangdu Hospotal
Xi'an, Shaanxi, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
Changchun, Jinlin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinjiang Uygur Autonomous Region People's Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Hospital of Tsinghua University
Beijing, Chaoyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Once-Daily pill ease nerve pain just as well as the standard Twice-Daily dose?
- Magnetic pulses aim to ease nerve pain without drugs
- Free digital tool could speed up chronic pain care in underserved areas
- Numbing patch may stop chronic pain after osteoporosis fractures
- Why do some patients still suffer pain after minimally invasive chest surgery?
- Could a daily cup of green tea extract ease cancer nerve pain?